Friday, April 3, 2020
Dongwha Pharm Signs Licensing-out MOU for Zabolante
‘Swift & Light’ Drug
Dongwha Pharm Signs Licensing-out MOU for Zabolante
  • By marie
  • April 7, 2016, 01:30
Share articles

Dongwha Pharm Co. CEO Sohn Ji-hoon (left) poses for a photo with Austell Laboratories (Pty) Ltd. Vice President Abdul Hafeez Mohamed.
Dongwha Pharm Co. CEO Sohn Ji-hoon (left) poses for a photo with Austell Laboratories (Pty) Ltd. Vice President Abdul Hafeez Mohamed.

 

Dongwha Pharm Co. signed a licensing-out MOU with South Africa’s Austell Laboratories (Pty) Ltd. for Zabolante, a quinolones antibiotic which acquired a new drug approval from the Ministry of Food and Drug Safety, at the Pharm Fair of the Bio Korea 2016.

Austell is the largest pharmaceutical company in South Africa showing the rapid growth. With the latest deal, Dongwha Pharm will be able to break into the African market, using South Africa as a base. 

An official from Dongwha Pharm said, “We are continuously having talks to launch Zabolante in Asia, the Commonwealth of Independent States including Russia, Latin America, as well as advanced markets such as Europe and the U.S.”

Zabolante was released in March 2016 and obtained approval for its phase III clinical trial involvingcommunity-acquired pneumonia from the US FDA.

The word “Zabolante” was derived from the name of its major ingredient, zabofloxacin, and the musical term “volante,” meaning swift and light, indicating its fast efficacy.